These data firstly indicated that DSCC1 might be involved in tumor-induced immunosuppression during the progression of LUAD and a potential biomarker for predicting therapeutic efficacy of PD-1/PD-L1 blockade treatment. The gene discussed is CD274; the disease is neoplasm.